David Roman Analyst PerformanceManaging Director | Global Investment Research at The Goldman Sachs GroupDavid Roman is a stock analyst at The Goldman Sachs Group focused in the medical sector, covering 21 publicly traded companies. Over the past year, David Roman has issued 23 stock ratings, including buy, hold, and sell recommendations. While full access to David Roman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Roman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings30 Last 10 YearsBuy Recommendations42.31% 11 Buy RatingsCompanies Covered21 Unique Companies Ratings Distribution26RatingsDistribution of strong buy, buy, hold, and sell ratings by David Roman.RatingPercentageCount Strong Buy3.8%1 ratings Buy38.5%10 ratings Hold38.5%10 ratings Sell19.2%5 ratingsOut of 26 total stock ratings issued by David Roman at The Goldman Sachs Group, the majority (38.5%) have been Buy recommendations, followed by 38.5% Hold, 19.2% Sell, and 3.8% Strong Buy.Best & Worst CallsBest Call000.0%BAXJul 2016Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call00.0%ZLTQOct 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ57.1% of companies on NASDAQ12 companiesNYSE42.9% of companies on NYSE9 companiesDavid Roman, an analyst at The Goldman Sachs Group, currently covers 21 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical18 companies85.7%Miscellaneous3 companies14.3%David Roman of The Goldman Sachs Group specializes in stock coverage within the Medical sector, with additional focus on companies.Coverage IndustriesIndustryPercentageMED PRODUCTS6 companies28.6%MEDICAL SERVICES4 companies19.0%MED INSTRUMENTS3 companies14.3%Miscellaneous3 companies14.3%MED/DENTAL - SUPP1 company4.8%CUSTOM COMPUTER PROGRAMMING SERVICES1 company4.8%MEDICAL INFO SYS1 company4.8%SURGICAL, MEDICAL, AND DENTAL INSTRUMENTS AND SUPPLIES1 company4.8%PHARMACEUTICAL PREPARATIONS1 company4.8% David Roman's Ratings History at The Goldman Sachs Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsCOOCooper Companies10/1/2025Set Price Target$68.53$64.00Sell$0.0000.00% ROIBLCOBausch + Lomb10/1/2025Initiated Coverage$15.08$16.00Neutral$0.0000.00% ROIGKOSGlaukos10/1/2025Initiated Coverage$81.67$103.00Buy$0.0000.00% ROIDOCSDoximity10/1/2025Set Price Target$73.22$64.00Sell$0.0000.00% ROIBBNXBeta Bionics10/1/2025Set Price Target$19.87$26.00Buy$0.0000.00% ROIIRTCiRhythm Technologies10/1/2025Boost Price Target$166.09$180.00Neutral$0.0000.00% ROIBBNXBeta Bionics10/1/2025Upgrade$20.21$26.00Buy$0.0000.00% ROIDOCSDoximity10/1/2025Reiterated Rating$70.67$64.00Sell$0.0000.00% ROIBLCOBausch + Lomb10/1/2025Initiated Coverage$14.76$16.00Neutral$0.0000.00% ROICOOCooper Companies10/1/2025Initiated Coverage$69.12$64.00Sell$0.0000.00% ROIGKOSGlaukos10/1/2025Initiated Coverage$84.56$103.00Buy$0.0000.00% ROISIShoulder Innovations8/25/2025Initiated Coverage$12.63$20.00Buy$0.0000.00% ROIOMDAOmada Health7/1/2025Initiated Coverage$18.30$29.00Buy$0.0000.00% ROIHQYHealthEquity6/4/2025Boost Price Target$113.10$104.00Neutral$0.0000.00% ROIBBNXBeta Bionics5/30/2025Initiated Coverage$15.36$16.00Neutral$0.0000.00% ROIZBHZimmer Biomet5/6/2025Lower Price Target$90.83$104.00Neutral$0.0000.00% ROIKMTSKestra Medical Technologies3/31/2025Initiated Coverage$23.43$24.00Neutral$0.0000.00% ROIGEHCGE HealthCare Technologies3/11/2025Upgrade$85.36$100.00Buy$0.0000.00% ROIABTAbbott Laboratories3/4/2025Boost Price Target$140.38$154.00Buy$0.0000.00% ROISOLVSolventum3/3/2025Boost Price Target$78.68$71.00Sell$0.0000.00% ROIBAXBaxter International2/26/2025Initiated Coverage$36.00$42.00Buy$0.0000.00% ROISYKStryker1/30/2025Boost Price Target$393.95$427.00Neutral$0.0000.00% ROIISRGIntuitive Surgical10/18/2024Set Price Target$521.89$604.00$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.